XML 54 R45.htm IDEA: XBRL DOCUMENT v3.26.1
License Agreements - Additional Information (Details) - USD ($)
 3 Months Ended 12 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Dec. 31, 2025
Dec. 31, 2022
Schedule Of License Agreement [Line Items]        
Research and development $ 14,379,000 $ 15,377,000    
License Agreement        
Schedule Of License Agreement [Line Items]        
Milestone payment       $ 100,000
Written notice period to terminated agreement 60 days      
Written notice period to terminated license agreement in event of breach of contract 30 days      
Uncured period of agreement in event of breach of agreement notice 60 days      
Written notice period for termination of agreement 90 days      
Termination period Description WARF may terminate the License Agreement with 90 days written notice if first commercial sale does not occur before December 31, 2031. Unless terminated earlier by the parties, the term of the License Agreement will continue until the last licensed patent expires in all countries.      
Research and development     $ 100,000  
License Agreement | Maximum        
Schedule Of License Agreement [Line Items]        
Potential milestone payments $ 800,000      
License Agreement | Investigation New Drug (IND) | Maximum        
Schedule Of License Agreement [Line Items]        
Expected milestone payment on achieving certain regulatory and commercial milestones 17,500,000      
License Agreement | Investigation New Drug (IND) | Minimum        
Schedule Of License Agreement [Line Items]        
Expected royalty payments upon first commercial product sale 100,000      
License Agreement | Research and Development        
Schedule Of License Agreement [Line Items]        
Upfront payment upon execution of agreement $ 300,000